Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(CDP-323; CDP 323; CDP323)
Zaurategrast Chemical Structure
|Product name: Zaurategrast|
|Cat. No.: HY-70073|
Zaurategrast(CDP-323) is an oral α4-integrin inhibitor.
CDP323 significantly decreased the capacity of lymphocytes to bind vascular adhesion molecule-1 (VCAM-1) and the expression of α4-integrin on VCAM-1-binding cells.CDP323 at daily doses of 1000 or 2000 mg induced significant increases in total lymphocyte count and suppressed VCAM-1 binding by reducing unbound very late antigen-4 expression on lymphocytes.
|M.Wt||521.41||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||1.9179 mL||9.5894 mL||19.1788 mL|
|5 mM||0.3836 mL||1.9179 mL||3.8358 mL|
|10 mM||0.1918 mL||0.9589 mL||1.9179 mL|
Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
CWHM-12 a novel small molecule inhibitor of (alpha)V integrins with IC50s of 1.8/0.8/1.5/0.2 nM for (alpha)v(beta)1/(alpha)v(beta)3/(alpha)v(beta)8; less potency on (alpha)v(beta)5(IC50=61 nM) and on inhibition on (alpha)IIb(beta)3/(alpha)2(beta)1/(alpha)10(beta)1.
Cyclo(-RGDfK) is a potent and selective inhibitor of the (alpha)v(beta)3 integrin.
Cyclo(RADfK) is a selective (alpha)(v)(beta)(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
E7820 is an angiogenesis inhibitorby suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells.
Firategrast is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS).
ILK-IN-1 is a novel ILK inhibitor with IC50 of 0.6 (mu)M.
ILK-IN-2 is a ILK inhibitor.
Integrin Antagonists 27 is a small molecule integrin (alpha)v(beta)3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.
TR-14035 is a a dual alpha4beta7(IC50=7 nM)/alpha4beta1 (IC50=87 nM) integrin antagonist .
Other Countries & RegionsSee Worldwide Distributors